CiPA update: in vitro cardiac ion channel screens, in silico models and stem cell iPS cardiomyocyte assays for proarrhythmia risk prediction

Presentation by Marc Rogers (Metrion CSO) at the June 2016 Sophion Ion Channel Modulation Symposium, Clare College, Cambridge (UK). CiPA update: in vitro cardiac ion channel screens, in silico models and stem cell iPS cardiomyocyte assays for proarrhythmia risk prediction.

Recommended Publications
Latest Publications
Webinar recording - Accelerating Pain Therapeutic Discovery: Nav1.9 as a Drug Target for Treatment of Pain

Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.

Development of a High-Throughput Automated Electrophysiology Assay for Human Nav1.9 Inhibitor Screening

Alex Haworth, Senior Scientist at Metrion, introduces a poster demonstrating Metrion's development of a monoclonal CHO cell line expressing hNav1.9, validated via manual and automated patch clamp techniques.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram